Table 1.
Baseline characteristics of participants.
| Variables | Before propensity matching | After propensity matching | ||||
|---|---|---|---|---|---|---|
| No anemia | Anemia | P-value | No anemia | Anemia | P-value | |
| Age | 0.097 | 0.645 | ||||
| <60 | 303(55.3%) | 102(48.6%) | 74(49.0%) | 78 (51.7%) | ||
| ≥60 | 245(44.7%) | 108(51.4%) | 77(51.0%) | 73 (48.3%) | ||
| Sex | 0.055 | 0.797 | ||||
| female | 186(33.9%) | 56 (26.7%) | 43(28.5%) | 41 (27.2%) | ||
| male | 362(66.1%) | 154(73.3%) | 108(71.5%) | 110(72.8%) | ||
| Smoking history | 0.005 | 0.555 | ||||
| Never | 284(51.8%) | 85 (40.5%) | 73 (48.3%) | 66 (43.7%) | ||
| Ever | 259(47.3%) | 119(56.7%) | 76 (50.3%) | 81 (53.6%) | ||
| unknown | 5 (0.9%) | 6 (2.9%) | 2 (1.3%) | 4 (2.6%) | ||
| ECOG PS | <0.001 | 0.171 | ||||
| <2 | 457(83.4%) | 152(72.4%) | 129(85.4%) | 119(78.8%) | ||
| ≥2 | 52 (9.5%) | 40 (19.0%) | 11 (7.3%) | 21 (13.9%) | ||
| unknown | 39 (7.1%) | 18 (8.6%) | 11 (7.3%) | 11 (7.3%) | ||
| BMI* | 0.005 | 0.925 | ||||
| <18.5 | 67 (12.6%) | 44 (22.0%) | 28 (18.5%) | 27 (17.9%) | ||
| ≥18.5, <25 | 398(74.8%) | 137(68.5%) | 109(72.2%) | 108(71.5%) | ||
| ≥25 | 67 (12.6%) | 19 (9.5%) | 14 (9.3%) | 16 (10.6%) | ||
| Pathology | <0.001 | 0.098 | ||||
| adenocarcinoma | 426(77.7%) | 138(65.7%) | 108(71.5%) | 107(70.9%) | ||
| squamous cell carcinoma | 101(18.4%) | 66 (31.4%) | 33 (21.9%) | 41 (27.2%) | ||
| others | 21 (3.8%) | 6 (2.9%) | 10 (6.6%) | 3 (2.0%) | ||
| Differentiation | 0.092 | 0.534 | ||||
| poor | 193(35.2%) | 74 (35.2%) | 47 (31.1%) | 56 (37.1%) | ||
| moderate | 48 (8.8%) | 31 (14.8%) | 15 (9.9%) | 18 (11.9%) | ||
| high | 18 (3.3%) | 5 (2.4%) | 5 (3.3%) | 3 (2.0%) | ||
| unknown | 289(52.7%) | 100(47.6%) | 84(55.6%) | 74(49.0%) | ||
| ALK fusion | 0.629 | 0.563 | ||||
| negative | 213(38.9%) | 74 (35.2%) | 62(41.1%) | 55(36.4%) | ||
| positive | 22(4.0%) | 8(3.8%) | 9(6.0%) | 7(4.6%) | ||
| unknown | 313(57.1%) | 128(61.0%) | 80 (53.0%) | 89 (58.9%) | ||
| EGFR mutation | 0.007 | 0.055 | ||||
| negative | 139(25.4%) | 56(26.7%) | 41(27.2%) | 45(29.8%) | ||
| positive | 110(20.1%) | 22(10.5%) | 35(23.2%) | 19(12.6%) | ||
| unknown | 299(54.6%) | 132(62.9%) | 75(49.7%) | 87(57.6%) | ||
| Sum of metastasis organs | 0.747 | 0.871 | ||||
| <2 | 102(18.6%) | 43(20.5%) | 27(17.9%) | 29(19.2%) | ||
| ≥2 | 435(79.4%) | 164(78.1%) | 121(80.1%) | 120(79.5%) | ||
| unknown | 11(2.0%) | 3(1.4%) | 3(2.0%) | 2(1.3%) | ||
| Treat type of 1st line therapy | 0.556 | 0.891 | ||||
| Chemo | 272(49.6%) | 106(50.5%) | 95(62.9%) | 99(65.6%) | ||
| TKI | 90(16.4%) | 28(13.3%) | 28(18.5%) | 26(17.2%) | ||
| others | 186(33.9%) | 76(36.2%) | 28(18.5%) | 26(17.2%) | ||
| Sum of treatment lines* | 0.257 | 0.123 | ||||
| ≤3 | 374(87.4%) | 147(90.7% | 127(84.1%) | 136(90.1%) | ||
| >3 | 54(12.6%) | 15(9.3%) | 24(15.9%) | 15(9.9%) | ||
ECOG PS: eastern cooperative group performance status, BMI: Body mass index, EGFR: epidermal growth factor receptor, ALK: Anaplastic Lymphoma Kinase, Treatment type of first-line therapy: Chemotherapy, Targeted therapy, others).
BMI* and Sum of treatment lines* had missing data.
*p values<0.05 were considered statistically significant.